Brean Capital set a $8.00 price objective on Intellipharmaceutics International Inc. (NASDAQ:IPCI) in a research report report published on Monday. The brokerage currently has a a buy rating on the stock.
Several other brokerages have also commented on IPCI. Maxim Group set a $6.00 target price on Intellipharmaceutics International and gave the company a buy rating in a research report on Thursday, October 6th. Zacks Investment Research upgraded Intellipharmaceutics International from a hold rating to a buy rating and set a $2.00 target price on the stock in a research report on Tuesday, September 13th.
Intellipharmaceutics International (NASDAQ:IPCI) traded down 7.39% on Monday, hitting $2.63. The company had a trading volume of 874,626 shares. Intellipharmaceutics International has a one year low of $1.41 and a one year high of $3.19. The stock’s market capitalization is $75.60 million. The stock has a 50 day moving average of $1.97 and a 200-day moving average of $1.84.
Intellipharmaceutics International (NASDAQ:IPCI) last announced its earnings results on Wednesday, July 13th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 325.20%. Equities analysts anticipate that Intellipharmaceutics International will post ($0.28) EPS for the current year.
An institutional investor recently bought a new position in Intellipharmaceutics International stock. Atria Investments LLC purchased a new stake in Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned approximately 0.27% of Intellipharmaceutics International at the end of the most recent quarter. 1.30% of the stock is currently owned by hedge funds and other institutional investors.
Intellipharmaceutics International Company Profile
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.